EyePoint, Inc. (EYPT)
About EyePoint, Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $31.4M
- Net income
- -$232.0M
- Total assets
- $364.0M
- Market cap
- $1.0B
- Operating margin
- -776.0%
- Net margin
- -739.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $31.4M
- Operating expenses
- $274.8M
- Operating income
- -$243.4M
- Income tax
- $279.0K
- Net income
- -$232.0M
- EPS (basic)
- $-3.17
- EPS (diluted)
- $-3.17
Balance sheet
- Total assets
- $364.0M
- Current assets
- $328.7M
- Total liabilities
- $57.9M
- Current liabilities
- $37.0M
- Shareholders’ equity
- $306.1M
Cash flow
- Operating cash flow
- -$240.1M
- Investing cash flow
- $68.6M
- Financing cash flow
- $173.6M
- Net cash flow
- $2.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.0B
- EPS (diluted)
- $-3.17
- Shares outstanding
- 78.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 27, 2005
EyePoint, Inc. (EYPT) Stock Price
- Reported a net loss of $232.0M in FY2025.
- Revenue declined 15% from FY2021 to FY2025.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review EyePoint, Inc..
Write a review
News about EyePoint, Inc.
News & sentiment via Polygon.io
EyePoint, Inc.: frequently asked questions
Is EyePoint, Inc. an American company?
EyePoint, Inc. is a US-based company headquartered in Watertown, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is EyePoint, Inc. headquartered?
EyePoint, Inc. is headquartered in Watertown, Massachusetts, United States.
Is EyePoint, Inc. publicly traded?
Yes — EyePoint, Inc. is a publicly traded company. Its stock trades under the ticker symbol EYPT on the NASDAQ.
What does EyePoint, Inc. do?
EyePoint, Inc. is an American Medical Devices company in the Health & Beauty sector.
